Allogene Therapeutics Inc’s filing revealed that its Officer Parker Geoffrey M. acquired Company’s shares for reported $0.1 million on Oct 21 ’24. In the deal valued at $2.84 per share,36,404 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Douglas Earl Martin bought 28,310 shares, generating $78,844 in total proceeds.
Before that, MESSEMER DEBORAH M. sold 18,641 shares. Allogene Therapeutics Inc shares valued at $42,488 were divested by the Director at a price of $2.28 per share. As a result of the transaction, MESSEMER DEBORAH M. now holds 166,765 shares, worth roughly $0.42 million.
A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in late May with a ‘”an Overweight”‘ rating. JMP Securities also remained covering ALLO and has decreased its forecast on January 05, 2024 with a “Mkt perform” recommendation from previously “Mkt outperform” rating. Guggenheim revised its rating on January 05, 2024. It rated ALLO as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ALLO
On Tuesday, Allogene Therapeutics Inc [NASDAQ:ALLO] saw its stock jump 10.53% to $2.52. Over the last five days, the stock has gained 18.87%. Allogene Therapeutics Inc shares have fallen nearly -21.50% since the year began. Nevertheless, the stocks have fallen -0.79% over the past one year. While a 52-week high of $5.78 was reached on 03/08/24, a 52-week low of $1.99 was recorded on 11/20/24. SMA at 50 days reached $2.67, while 200 days put it at $3.09.
Levels Of Support And Resistance For ALLO Stock
The 24-hour chart illustrates a support level at 2.38, which if violated will result in even more drops to 2.25. On the upside, there is a resistance level at 2.71. A further resistance level may holdings at 2.91. The Relative Strength Index (RSI) on the 14-day chart is 49.26, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.31%. Stochastics %K at 25.31% indicates the stock is a holding.
How much short interest is there in Allogene Therapeutics Inc?
A steep rise in short interest was recorded in Allogene Therapeutics Inc stocks on 2024-11-15, dropping by -4.27 million shares to a total of 35.05 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 39.32 million shares. There was a decline of -12.19%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 08, 2023 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.
